Tocilizumab and other targeted therapies for severe cutaneous immune-related adverse events.

Tocilizumab and other targeted therapies for severe cutaneous immune-related adverse events. Br J Dermatol. 2020 Sep 06;: Authors: Thompson LL, Chen ST PMID: 32892364 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32892364?dopt=Abstract

Source: The British Journal of Dermatology - September 5, 2020 Category: Dermatology Authors: Thompson LL, Chen ST Tags: Br J Dermatol Source Type: research

More News: Actemra | Dermatology | Skin | UK Health